Updated information and services can be found at:
Whooping cough is quite common and can be diagnosed clinically
Editor-Harnden et al, with the help of a recently available blood test, have gone some way to confirm that whooping cough is still about.
1 Since 1977, I have, with the help of my practice colleagues, been recording every clinically diagnosable case of whooping cough (based on a minimum of three weeks of paroxysmal coughing). This year so far we have seen six cases in a practice of 11 000. In 2002 we recorded 44 cases. Ten had blood specimens tested; nine were positive and the 10th was lost. Twenty three had pernasal swabs taken; 14 were positive. This small practice was responsible for 5% of all whooping cough notifications in England and Wales in 2002. This surely cannot be because there is more whooping cough where I work.
I have had four papers published in the BMJ as a result of this study.
2-5 I have decided to publish the incidence data on the web. Some years ago I set up a website to help patients diagnose their own whooping cough, and I can confirm from the feedback that doctors the world over seem to be equally poor at diagnosing it. I have published the Keyworth figures (www.whoopingcough.net/keyworth). Basic data on all cases are available, as well as year-on-year figures compared with national notifications (figure).
Whooping cough is a distressing illness, especially when it is undiagnosed. I am hopeful that the paper by Harnden et al will wake us up about this disease, which, if my data are correct, is just as common as it was 25 years ago after the vaccine scare settled.
Competing interests: DJ has a website on whooping cough that charges a fee for personal advice. The fees have so far never covered the expenses for the site. 
Author's reply to review of his book on autism
Editor-The misrepresentations and omissions in Fitzgerald's review of my book demand correction. 1 The book overviews evidence for (and against) the apparent rise in autism and concludes that the increase is probably real-pointing to an environmental risk factor so far unknown.
A focus of the book is on physiological dysregulation that accompanies and exacerbates autism. It reviews evidence that limbic damage can both cause and reflect physiological problems, with environmental toxins including heavy metals having a causal role, although concluding that the rise in autism cannot be uniquely attributed to such exposure (but it remains a strong suspect). Just one short chapter refers to possible strategies for treatment and prevention.
Fitzgerald focuses his critical attentions only on this chapter: most of the book is not addressed. He asserts that there is no coherent scientific rationale for the treatments and little evidence of their efficacy. He omits to note the considered position taken by the book, that the field is fraught with uncertainty because few logical therapeutic approaches have been evaluated systematically. Reviewer and author are therefore substantially in agreement.
Fitzgerald then draws attention to an autistic boy who died while receiving chelation treatment. This is also misleading: use of the wrong drug was responsible for the death. He then says that guidelines from the American Academy of Neurology explicitly reject a series of biomedical tests. 3 The recommendations speak not of rejection but of inadequate supporting evidence, a different matter. This is an area of debate.
Regarding biomedical intervention, affected children should be spared unproved treatments until efficacy has been shown in controlled trials. Trials (examples include haloperidol, risperidone, methylphenidate hydrochloride (Ritalin)) have been conducted through mainstream medicine and not by (in the words of Fitzgerald) quacks and charlatans. Valproate continues to be prescribed for epilepsy associated with autism, even though valproic acid is a known cause of autism. Fitzgerald's exclusive focus on therapeutic options is unfortunate, for this is a minor aspect. The central thesis offered by the book is of a rational and plausible sequence of events that causes as well as exacerbates autism-addressed by Fitzgerald as "speculative."
Rushing into biomedical remediation without fullest consideration of justification and efficacy is a mistake, but it is an equally grave error to dismiss without objective consideration of all the evidence (as laid out in the book), and new research under way, 5 an environmental and physiological contribution to autism. 
Richard Lathe neuroscience consultant

What works in schizophrenia
Depot preparations may improve outcomes
Editor-The study by Tiihonen et al indicates that antipsychotics are not equally effective in treating schizophrenia.
1 After a first admission with schizophrenia, patients treated with clozapine, olanzapine, or perphenazine depot had substantially lower risks of readmission, and discontinuation of treatment for any reason, than patients treated with oral haloperidol.
The increased effectiveness of clozapine is understandable in terms of its superior efficacy in treatment resistant schizophrenia.
2
The increased effectiveness of perphenazine depot presumably derives from its ability to reduce non-compliance, a common problem in schizophrenia that can be overt or covert.
3 In the study reported by Tiihonen et al, the less favourable outcome for oral perphenazine, in contrast to the depot preparation, supports this hypothesis.
The effectiveness of clozapine and perphenazine depot may also partly reflect the regular clinical contact and supervision that are integral to both treatments; with a depot this relates to its administration and with clozapine to regular haematological monitoring. The results are unlikely to reflect a prescribing bias as depots are largely used in patients who comply poorly with oral drugs and clozapine is restricted to use in treatment resistant schizophrenia.
Despite its effectiveness, perphenazine depot was not commonly used. This may reflect negative perceptions about depots. 4 In a Cochrane review a greater proportion of patients treated with depot than with oral drugs showed global improvement, perhaps reflecting depots reducing partial compliance. 5 The work of Tiihonen et al adds to the view that depot antipsychotic drugs are effective for some patients. Like all antipsychotic drugs, they should be prescribed on an individual basis after full discussion with the patient and considering a range of factors.
Pharmacologically, clinical outcomes in schizophrenia can be improved by using drugs that are either more efficacious or improve compliance, and one way to do this is to use a depot preparation. 
Cognitive behaviour therapy is not effective
Editor-Kingdon's statement that more than 20 randomised controlled trials and five meta-analyses have shown cognitive behaviour therapy to be beneficial in schizophrenia gives an oversimplified picture of both the randomised controlled trials and the meta-analyses.
1
Reviewing the randomised controlled trials, Tarrier and Wykes, two supporters of cognitive behaviour therapy in schizophrenia, noted that five included groups who received befriending, supportive counselling, or problem solving to control for the non-specific effects of intervention, in other words as a psychological placebo.
2 They said that not one study has shown clear and significant overall differences between cognitive behaviour therapy and the non-specific control groups.
3
The conclusion of the Cochrane Collaboration's meta-analysis of cognitive behaviour therapy for schizophrenia was currently that trial based data supporting the wide use of such treatment for people with schizophrenia or other psychotic illnesses are far from conclusive.
3 Compared with standard care, cognitive behaviour therapy was found not to reduce relapse and readmission; it helped mental state over the medium term but after one year the difference had gone, and it did not show a consistent effect on continuous measures of mental state. Compared with supportive psychotherapy, cognitive behaviour therapy had no effect on relapse or on the outcome "no clinically meaningful improvements in mental state" over the same time periods.
Behind all the recent publicity surrounding cognitive behaviour therapy for schizophrenia, the truth is that it works only in poorly controlled trials and not in well controlled ones. 
Peter J McKenna professor of psychiatry
Fluoroquinolone resistance in Salmonella Typhi
Editor-As Parry et al point out, 1 2 appropriate laboratory methods are crucial in detecting clinically important quinolone resistance.
We highlight the emergence of strains of Salmonella enterica serovar Typhi (S Typhi) that show reduced susceptibility to the fluoroquinolones but are susceptible to nalidixic acid (minimum inhibitory concentration < 16 mg/l). In a review of all 692 isolates of S Typhi sent to the Laboratory for Enteric Pathogens at the Health Protection Agency in London between 2000 and 2003 we detected 49 isolates that were susceptible to nalidixic acid but had reduced susceptibility to fluoroquinolone (minimum inhibitory concentration 0.125-1.0 mg/l; table).
3 When the country of acquisition was known, 18 of these isolates were from patients who had visited India; eight, Pakistan; four, Bangladesh; and one, Kenya.
Overall, of 271 isolates with reduced susceptibility to fluoroquinolone, 18% were susceptible to nalidixic acid and therefore would not have been detected by routine screening with a nalidixic acid disc. No clinical outcome data are available and so the clinical relevance of these strains is uncertain, but an enhanced surveillance study is being undertaken by the Health Protection Agency. 4 Although resistance to nalidixic acid (minimum inhibitory concentration > 256 mg/l) remains an important marker for failure of fluoroquinolone treatment in typhoid fever, several isolates show reduced susceptibility to fluoroquinolone while remaining susceptible to nalidixic acid. This is particularly true for isolates from the Indian subcontinent. Furthermore, in six of the 49 such isolates ( 
An independent NHS?
Why it really is time to separate from direct government involvement
Editor-I received 21 items of correspondence about my personal view on separating the NHS from direct government involvement, mostly supporting the idea and many urging me to take it further. 1 I have worked in the NHS for 28 years and my conclusions are based on first hand experience of the waste associated with massive bureaucracy to support edicts from the top, short term solutions to satisfy the ruling party's election prospect, and, most damaging of all, the three yearly cycle of NHS reforms.
There is lack of confidence in any health minister, their handful of civil servants, and their chosen "advisers" in ever producing policies that are foremost for the benefit of the country without worrying about their position and their party's election prospect.
The model I am suggesting would remove this monolithic self interest. The model is apolitical, has input from all parties, and is not an unaccountable quango or technocracy of professionals. It is new, unique, democratic, and accountable to parliament with the necessary regulations to ensure its effectiveness. Such reform would be the least costly in the history of the NHS. The only change would be the people who sit around the decision making table and their advisers. All it needs is men and women with courage and conviction to put their country before their party.
If such a body came to the conclusion that we should overtly ration health care, the country would listen and better trust its motives. If it concluded that some input from the private sector was inevitable, the country would listen and might reluctantly accept but trust the source of that decision.
To Gordon Brown, I say, one more bold decision, and the country will remember who saved the NHS. To David Cameron, if Brown misses this opportunity then it's your chance to double your prospect of winning. To my colleagues, please speak up as advocates for your patients and your communities.
